MX2024012034A - Ácidos nucleicos antisentido para usarse en el tratamiento de portadores de mutaciones lmna - Google Patents

Ácidos nucleicos antisentido para usarse en el tratamiento de portadores de mutaciones lmna

Info

Publication number
MX2024012034A
MX2024012034A MX2024012034A MX2024012034A MX2024012034A MX 2024012034 A MX2024012034 A MX 2024012034A MX 2024012034 A MX2024012034 A MX 2024012034A MX 2024012034 A MX2024012034 A MX 2024012034A MX 2024012034 A MX2024012034 A MX 2024012034A
Authority
MX
Mexico
Prior art keywords
treatment
antisense nucleic
nucleic acids
mutation carriers
lmna mutation
Prior art date
Application number
MX2024012034A
Other languages
English (en)
Spanish (es)
Inventor
Yigal- Martin Pinto
Anke Johanna Marina Tijsen
Vries Dylan Kristanto De
Original Assignee
Stichting Amsterdam UMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Amsterdam UMC filed Critical Stichting Amsterdam UMC
Publication of MX2024012034A publication Critical patent/MX2024012034A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Analytical Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
MX2024012034A 2022-03-30 2024-09-27 Ácidos nucleicos antisentido para usarse en el tratamiento de portadores de mutaciones lmna MX2024012034A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22165710 2022-03-30
PCT/NL2023/050168 WO2023191631A1 (en) 2022-03-30 2023-03-30 Antisense nucleic acids for use in the treatment for lmna mutation carriers

Publications (1)

Publication Number Publication Date
MX2024012034A true MX2024012034A (es) 2025-03-07

Family

ID=81074125

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024012034A MX2024012034A (es) 2022-03-30 2024-09-27 Ácidos nucleicos antisentido para usarse en el tratamiento de portadores de mutaciones lmna

Country Status (9)

Country Link
US (1) US20260002152A1 (https=)
EP (1) EP4499826A1 (https=)
JP (1) JP2025513932A (https=)
KR (1) KR20250021303A (https=)
CN (1) CN119790153A (https=)
AU (1) AU2023246365A1 (https=)
CA (1) CA3246987A1 (https=)
MX (1) MX2024012034A (https=)
WO (1) WO2023191631A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025096498A1 (en) * 2023-10-30 2025-05-08 Research Institute At Nationwide Children's Hospital Compositions and methods for treating diseases or conditions associated with progerin expression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
WO2007047913A2 (en) * 2005-10-20 2007-04-26 Isis Pharmaceuticals, Inc Compositions and methods for modulation of lmna expression
WO2020061497A1 (en) * 2018-09-20 2020-03-26 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of lmna expression

Also Published As

Publication number Publication date
WO2023191631A1 (en) 2023-10-05
JP2025513932A (ja) 2025-04-30
US20260002152A1 (en) 2026-01-01
AU2023246365A1 (en) 2024-10-17
CA3246987A1 (en) 2023-10-05
EP4499826A1 (en) 2025-02-05
KR20250021303A (ko) 2025-02-12
CN119790153A (zh) 2025-04-08

Similar Documents

Publication Publication Date Title
Niehrs et al. Regulatory R-loops as facilitators of gene expression and genome stability
US10760081B2 (en) Compositions and methods for enhancing CRISPR activity by POLQ inhibition
Duechler et al. Nucleoside modifications in the regulation of gene expression: focus on tRNA
Lee et al. MicroRNA-124 regulates osteoclast differentiation
Chen et al. Preferential production of RNA rings by T4 RNA ligase 2 without any splint through rational design of precursor strand
WO2020205605A3 (en) OLIGONUCLEOTIDE-BASED MODULATION OF C9orf72
IN2014CN04590A (https=)
Yan et al. MicroRNA‐22 promoted osteogenic differentiation of human periodontal ligament stem cells by targeting HDAC6
JP2017517268A5 (https=)
MX2024012034A (es) Ácidos nucleicos antisentido para usarse en el tratamiento de portadores de mutaciones lmna
AU2019252204A2 (en) Novel small activating RNA
CN104212836A (zh) 一种在哺乳动物细胞系中敲除mir-505的方法
CN106032532A (zh) 一种小激活rna及其制备方法和应用
BRPI0413542A (pt) molécula isolada de polinucleotìdeo, polipeptìdeo, molécula de dna recombinante, vetor de expressão, organismo recombinante, bem como processos para produção de ácido l-ascórbico, de l-sorbosona desidrogenase e de vitamina c
EP2046970B2 (en) A method of producing recombinant biological products
US9834768B2 (en) Effective method for specific gene silencing using artificial small RNA
Klanert et al. Endogenous microRNA clusters outperform chimeric sequence clusters in Chinese hamster ovary cells
Pereira et al. Affinity approaches in RNAi-based therapeutics purification
JP2025023131A (ja) 治療的使用のための、ヒト遺伝子ＪＡＫ１又はＪＡＫ３の発現を標的とするＳｉＲＮＡ配列
Morlon et al. The complete nucleotide sequence of the colicinogenic plasmid ColA. High extent of homology with ColE1
Murina et al. Bacterial small regulatory RNAs and Hfq protein
US9970004B2 (en) Nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell, induction method of RNA interferencde in eukaryotic host and use of the nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide CAG repeats
Bobrowicz et al. Polyadenylation and degradation of mRNA in mammalian mitochondria: a missing link?
Stiefel et al. Noncoding RNAs, post-transcriptional RNA operons and Chinese hamster ovary cells
JP2016532445A (ja) 組換えタンパク質の生産のための哺乳動物生産細胞の生成のための手段及び方法